WO2009044547A1 - 神経細胞死抑制剤 - Google Patents
神経細胞死抑制剤 Download PDFInfo
- Publication number
- WO2009044547A1 WO2009044547A1 PCT/JP2008/002768 JP2008002768W WO2009044547A1 WO 2009044547 A1 WO2009044547 A1 WO 2009044547A1 JP 2008002768 W JP2008002768 W JP 2008002768W WO 2009044547 A1 WO2009044547 A1 WO 2009044547A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell death
- nerve cell
- death inhibitor
- inhibitor
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08836702T ES2389392T3 (es) | 2007-10-03 | 2008-10-02 | Inhibidor de la muerte de las neuronas |
JP2009535978A JP5399909B2 (ja) | 2007-10-03 | 2008-10-02 | 神経細胞死抑制剤 |
DK08836702.4T DK2193793T3 (da) | 2007-10-03 | 2008-10-02 | Nervecelle-døds-inhibitor |
CN200880109935A CN101815517A (zh) | 2007-10-03 | 2008-10-02 | 神经细胞死亡抑制剂 |
EP08836702A EP2193793B1 (en) | 2007-10-03 | 2008-10-02 | Nerve cell death inhibitor |
PL08836702T PL2193793T3 (pl) | 2007-10-03 | 2008-10-02 | Inhibitor śmierci komórek nerwowych |
CA2701397A CA2701397C (en) | 2007-10-03 | 2008-10-02 | Nerve cell death inhibitor |
KR1020107006970A KR101503782B1 (ko) | 2007-10-03 | 2008-10-02 | 신경 세포사 억제제 |
US12/676,265 US7973053B2 (en) | 2007-10-03 | 2008-10-02 | Nerve cell death inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-259682 | 2007-10-03 | ||
JP2007259682 | 2007-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009044547A1 true WO2009044547A1 (ja) | 2009-04-09 |
Family
ID=40525979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/002768 WO2009044547A1 (ja) | 2007-10-03 | 2008-10-02 | 神経細胞死抑制剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7973053B2 (ja) |
EP (1) | EP2193793B1 (ja) |
JP (1) | JP5399909B2 (ja) |
KR (1) | KR101503782B1 (ja) |
CN (1) | CN101815517A (ja) |
CA (1) | CA2701397C (ja) |
CY (1) | CY1113364T1 (ja) |
DK (1) | DK2193793T3 (ja) |
ES (1) | ES2389392T3 (ja) |
PL (1) | PL2193793T3 (ja) |
PT (1) | PT2193793E (ja) |
TW (1) | TWI432195B (ja) |
WO (1) | WO2009044547A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018000228A1 (zh) | 2016-06-29 | 2018-01-04 | 北京小米移动软件有限公司 | 数据传输方法、装置和终端 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6479151A (en) | 1987-06-22 | 1989-03-24 | Eisai Co Ltd | Cyclic amine derivative |
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
JPH11171861A (ja) | 1997-12-12 | 1999-06-29 | Eisai Co Ltd | ドネペジルの製造法 |
JPH11263774A (ja) | 1998-01-16 | 1999-09-28 | Eisai Co Ltd | ドネペジル誘導体の製造法およびその中間体 |
WO1999048488A2 (en) | 1998-03-23 | 1999-09-30 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
WO2000028981A2 (en) | 1998-11-13 | 2000-05-25 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
WO2001032161A2 (en) | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
WO2001096311A2 (en) | 2000-06-15 | 2001-12-20 | Bristol-Myers Squibb Company | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
WO2002062824A2 (en) | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid ? precursor disorder |
WO2005099823A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
WO2007088705A1 (ja) | 2006-01-31 | 2007-08-09 | Kowa Co., Ltd. | 糖尿病治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1492539T3 (da) | 2002-04-02 | 2006-10-30 | Janssen Pharmaceutica Nv | Statin-terapi til forögelse af kognitiv funktion |
BRPI0408491A (pt) * | 2003-03-19 | 2006-04-04 | Ares Trading Sa | tratamento da doença de alzheimer |
JPWO2005063294A1 (ja) | 2003-12-30 | 2007-12-13 | 興和株式会社 | γ−セクレターゼ複合体形成阻害剤 |
-
2008
- 2008-09-30 TW TW097137428A patent/TWI432195B/zh not_active IP Right Cessation
- 2008-10-02 WO PCT/JP2008/002768 patent/WO2009044547A1/ja active Application Filing
- 2008-10-02 KR KR1020107006970A patent/KR101503782B1/ko active IP Right Grant
- 2008-10-02 CA CA2701397A patent/CA2701397C/en not_active Expired - Fee Related
- 2008-10-02 ES ES08836702T patent/ES2389392T3/es active Active
- 2008-10-02 JP JP2009535978A patent/JP5399909B2/ja not_active Expired - Fee Related
- 2008-10-02 EP EP08836702A patent/EP2193793B1/en not_active Not-in-force
- 2008-10-02 CN CN200880109935A patent/CN101815517A/zh active Pending
- 2008-10-02 US US12/676,265 patent/US7973053B2/en not_active Expired - Fee Related
- 2008-10-02 PL PL08836702T patent/PL2193793T3/pl unknown
- 2008-10-02 DK DK08836702.4T patent/DK2193793T3/da active
- 2008-10-02 PT PT08836702T patent/PT2193793E/pt unknown
-
2012
- 2012-10-31 CY CY20121101047T patent/CY1113364T1/el unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6479151A (en) | 1987-06-22 | 1989-03-24 | Eisai Co Ltd | Cyclic amine derivative |
JPH07252216A (ja) | 1987-06-22 | 1995-10-03 | Eisai Co Ltd | 環状アミン誘導体 |
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US5856336A (en) | 1987-08-20 | 1999-01-05 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
JPH11171861A (ja) | 1997-12-12 | 1999-06-29 | Eisai Co Ltd | ドネペジルの製造法 |
JPH11263774A (ja) | 1998-01-16 | 1999-09-28 | Eisai Co Ltd | ドネペジル誘導体の製造法およびその中間体 |
US6080778A (en) | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
WO1999048488A2 (en) | 1998-03-23 | 1999-09-30 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6440387B1 (en) | 1998-03-23 | 2002-08-27 | Children's Medical Center Corporation | Methods for determining risk of Alzheimer's disease |
WO2000028981A2 (en) | 1998-11-13 | 2000-05-25 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
JP2002529500A (ja) * | 1998-11-13 | 2002-09-10 | ナイモックス コーポレーション | HMGCoAレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法 |
US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
WO2001032161A2 (en) | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
WO2001096311A2 (en) | 2000-06-15 | 2001-12-20 | Bristol-Myers Squibb Company | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
WO2002062824A2 (en) | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid ? precursor disorder |
WO2005099823A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
WO2007088705A1 (ja) | 2006-01-31 | 2007-08-09 | Kowa Co., Ltd. | 糖尿病治療剤 |
Non-Patent Citations (7)
Title |
---|
CHIE OKI ET AL.: "Ikkasei No Kyoketsu Sunanezumi no Chihatsusei Shinkei Saiboshi ni Taisuru Pitavastatin (HMG-CoA Kangen Koso Sogaiyaku) no Kosanka Sayo", THERAPEUTIC RESEARCH, vol. 26, no. 6, 2005, pages 1277 - 1286 * |
KUMAGAI ET AL., J. NEURAL. TRANSM., vol. 111, 2004, pages 1103 - 1120 |
MIIDA, PHARMACOL. THER., vol. 113, pages 378 - 393 |
MIIDA, T. ET AL.: "Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects", PHARMACOL THER, vol. 113, no. 2, 2007, pages 378 - 393 * |
ROMAN ET AL., EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 16, no. 4, 2006, pages S481 - S482 |
See also references of EP2193793A4 * |
TOUNAI ET AL., METAB BRAIN DIS, vol. 22, 2007, pages 89 - 104 |
Also Published As
Publication number | Publication date |
---|---|
KR101503782B1 (ko) | 2015-03-18 |
EP2193793B1 (en) | 2012-08-01 |
CA2701397A1 (en) | 2009-04-09 |
PT2193793E (pt) | 2012-09-28 |
EP2193793A4 (en) | 2011-02-09 |
TWI432195B (zh) | 2014-04-01 |
DK2193793T3 (da) | 2012-08-20 |
JPWO2009044547A1 (ja) | 2011-02-03 |
ES2389392T3 (es) | 2012-10-25 |
CY1113364T1 (el) | 2016-06-22 |
PL2193793T3 (pl) | 2012-12-31 |
US7973053B2 (en) | 2011-07-05 |
KR20100072227A (ko) | 2010-06-30 |
EP2193793A1 (en) | 2010-06-09 |
TW200918059A (en) | 2009-05-01 |
US20100173938A1 (en) | 2010-07-08 |
CN101815517A (zh) | 2010-08-25 |
CA2701397C (en) | 2015-11-03 |
JP5399909B2 (ja) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130399T1 (hr) | Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti | |
IL198411A0 (en) | Haloalkylsulfonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide | |
EP2607348A3 (en) | Plasminogen Activator Inhibitor-1 Inhibitor | |
WO2006120176A3 (en) | Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative | |
WO2009072604A1 (ja) | 抗nr10抗体、およびその利用 | |
EP2089354A4 (en) | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING HISTONE DEACETYLASE INHIBITORY ACTIVITY AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
WO2010009139A3 (en) | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors | |
WO2008094737A3 (en) | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | |
GB0509224D0 (en) | Inhibitors of intracellular enzymatic activity | |
IL191542A0 (en) | Use of phenyl-hydrazine- indole derivatives for the manufacture fo medicaments for modulating thrombopoietin activity | |
WO2008073138A3 (en) | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors | |
WO2007121125A3 (en) | Hcv inhibitors | |
WO2006083924A8 (en) | 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors | |
WO2006075256A3 (en) | 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity | |
AU2005273867A1 (en) | Benzothienopyridines for use as inhibitors of Eg5 kinesin | |
WO2009041663A1 (ja) | 皮膚疾患の予防及び/または治療剤 | |
ZA200710414B (en) | Agent for regeneration and/or protection of nerves | |
WO2008031817A3 (en) | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors | |
EP1945606A4 (en) | ALKYLCARBAMOYLNAPHTALENYLOXYOCTENOYLHYDROXYAMIDE DERIVATIVES HAVING HISTONE DEACETYLASE INHIBITORY ACTIVITY AND SYNTHESIS OF THE DERIVATIVES | |
EP4174064A4 (en) | TETRAHYDROISOCINOLINE COMPOUNDS AND THEIR USE | |
WO2009043170A8 (en) | Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors | |
WO2008081580A1 (ja) | 環状ホスファチジン酸誘導体を含む鎮痛剤 | |
WO2008006883A3 (en) | Benzopyranopyrazoles | |
EP2006287A4 (en) | COMPOUND HAVING ANTIMALARIAL ACTIVITY AND ANTIMALARIAL DRUG CONTAINING IT AS AN ACTIVE SUBSTANCE | |
WO2008033389A3 (en) | Macrocyclic hcv inhibitors and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880109935.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08836702 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12676265 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008836702 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107006970 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2701397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009535978 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |